Superiority of <scp>Low‐Dose</scp> Benzbromarone <scp>Add‐On</scp> to <scp>Low‐Dose</scp> Febuxostat Compared With Febuxostat Monotherapy in Gout With <scp>Combined‐Type</scp> Hyperuricemia
Xiaomei Xue(Qingdao University), Changgui Li(Guilin University of Aerospace Technology), Aichang Ji(Qingdao University), Xuan Yuan(Qingdao University), Fei Yan(Qingdao University), Yuwei He(Qingdao University), Han Qi(Qingdao University), Robert Terkeltaub(University of California San Diego), Ying Chen(Qingdao University), Nicola Dalbeth(University of Auckland), Mingshu Sun(Qingdao University), Maichao Li(Qingdao University), Xinde Li(Qingdao University)
Cited by 10
Related Papers
GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes
|Annals of the Rheumatic Diseases|2016|173
Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease
|The American Journal of Medicine|2021|122
Parathyroid hormone–related peptide is a naturally occurring, protein kinase A–dependent angiogenesis inhibitor
|Nature Medicine|2002|102
Superiority of <scp>Low‐Dose</scp> Benzbromarone to <scp>Low‐Dose</scp> Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion
|Arthritis & Rheumatology|2022|60
Metabolomics and Machine Learning Identify Metabolic Differences and Potential Biomarkers for Frequent Versus Infrequent Gout Flares
|Arthritis & Rheumatology|2023|32